Indivior Pharmaceuticals Announces Merger with Supernus; Investor Call

What Happened

• Indivior Pharmaceuticals, Inc. announced that it and Supernus Pharmaceuticals, Inc. executed an Agreement and Plan of Merger dated August 1, 2026, and held a joint conference call and investor presentation on August 3, 2026 to discuss the transaction. The merger involves Artemis Merger Sub Inc., a wholly owned subsidiary of Indivior. The investor presentation was furnished as Exhibit 99.1 to the Form 8‑K.

Key Details

• Merger agreement date: August 1, 2026.
• Public event: Joint conference call and investor presentation on August 3, 2026; presentation filed as Exhibit 99.1.
• Regulatory filings planned: Indivior intends to file a registration statement on Form S‑4 that will include a joint proxy statement/prospectus for Indivior and Supernus.
• Noted risks: The filing highlights common closing risks — required stockholder and regulatory approvals, potential delays or termination, fixed exchange ratio, additional indebtedness to fund a Special Dividend, integration costs, and other factors that could affect completion or expected benefits.

Why It Matters

• For investors, this announces a material strategic transaction (described as a proposed merger of equals) that will require shareholder votes and SEC review via a Form S‑4 and joint proxy statement/prospectus. The documents to be filed will contain important details on the transaction terms, expected benefits and risks, financing (including any Special Dividend-related debt), and timing. Investors should read the forthcoming joint proxy statement/prospectus when available and monitor filings on www.sec.gov for definitive terms before making voting or investment decisions.